Patents by Inventor Annalisa Macagno

Annalisa Macagno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10975144
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 13, 2021
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Publication number: 20210087257
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 25, 2021
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 10941198
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 9, 2021
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Patent number: 10889632
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 12, 2021
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 10875916
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 29, 2020
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno, Shimobi Onuoha
  • Publication number: 20200017575
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: July 31, 2019
    Publication date: January 16, 2020
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 10414817
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 17, 2019
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20190250163
    Abstract: A method for collecting information about the health status of a subject is proposed involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of THBS1, the proportion of free PSA (% fPSA), preferably including the concentration of at least one protein selected from the group consisting of CTSD, OLFM4, ICAM1.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 15, 2019
    Applicant: ProteoMedix AG
    Inventors: Ralph SCHIESS, Kathrin ENDT, Alcibiade ATHANASIOU, Annalisa MACAGNO, Thomas STEUBER
  • Publication number: 20190112367
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: August 21, 2018
    Publication date: April 18, 2019
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Publication number: 20190071499
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 7, 2019
    Inventors: Syeda F. Y. HAQUE, Adrian HAYDAY, Kai KISAND, Kai KROHN, Annalisa MACAGNO, Steffen MEYER, Paert PETERSON, Mike ROTHE, Philip VLAICU, Martin WOODWARD
  • Publication number: 20190023779
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 24, 2019
    Inventors: Adrian HAYDAY, Kai KROHN, Annamari RANKI, Part PETERSON, Kai KISAND, Edward STUART, Annalisa MACAGNO, Shimobi ONUOHA
  • Publication number: 20180371062
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: July 2, 2018
    Publication date: December 27, 2018
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 10131709
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 20, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno, Shimobi Onuoha
  • Patent number: 10112995
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 30, 2018
    Assignee: ImmunoQure AG
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Patent number: 10081676
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: September 25, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Patent number: 10040845
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 7, 2018
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 9957319
    Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: May 1, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
  • Publication number: 20180086819
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: March 29, 2018
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20170334972
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 23, 2017
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 9803000
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 31, 2017
    Assignee: Institute of Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno